Side
Effects or Symptoms > HAMA
(human anti-mouse antibodies)
Last update: 03/16/2007
Fatigue
| Quick
Reference | Resources & Research News
|
 TOPIC
SEARCH: PubMed
| Web
HAMA
Human Anti-Mouse
Antibodies. A mouse antibody administered to a human is seen by the
human immune system as a foreign protein (antigen).
The human immune system generates its own human antibodies against
the introduced mouse antibody (the HAMA response).
The HAMA response can create problems such as allergic-like reaction
to the mouse antibody, rapid removal of the mouse antibody, and weak
ability to recruit human immune system processes necessary to clear
the targeted antigen (e.g. tumor cell).
The first may generate additional health problems in a patient while
the latter two reduce the efficacy of the mouse antibody as a
therapeutic. - Genentech gene.com
HAMA as a Side Effect of Treatment
 |
"About
one-third of patients with relapsed B-cell malignancies develop
human
anti-mouse antibody (HAMA) following mouse antibody treatment"
- Survival benefit associated with human anti-mouse antibody
(HAMA) in patients with B-cell malignancies - springerlink.com
|
|
"Although
approximately 10% of patients treated with tositumomab and
iodine I 131 tositumomab (bexxar) developed
human-anti-mouse antibodies, treatment with tositumomab
does not preclude the administration of subsequent
chimeric (mouse-human) antibody therapies."
- A clinical and scientific overview of tositumomab and
iodine I 131 tositumomab.
Semin Oncol. 2003 Apr;30(2 Suppl 4):22-30. Review. PMID: 12728404
|
|
If a person makes HAMA, they
could have a serious allergic reaction to any other drug
or
diagnostic test that was made from mouse protein, or it could
affect how well the drug or
diagnostic test worked.
Bexxar for NHL - http://www.bexxar.com/patients/bexxar_patientsmain.html
|
|
Does Development of HAMA After Tositumomab (Bexxar) Preclude
Subsequent Therapy
With Rituximab (Rituxan)? -
Development of HAMA can occur after exposure to tositumomab,
especially in patients who have not received prior chemotherapy
for their disease.
In this group who receive "front-line" tositumomab, HAMA
antibodies have been demonstrated in as many as 64%. In a study by
Mark S. Kaminski, from the University of Michigan, Ann
Arbor,
Michigan, and colleagues,[5] 22 patients with HAMA responses to
tositumomab were studied,
and 6 were found to have high titer (> 500 mg/mL)
antibody.
Thirteen of these patients subsequently received rituximab.
Although response rates were
not reported, it is important to note that there was no evidence
of increased severity or frequency
of infusion reactions. Therefore, it seems that rituximab can be
given safely after development
of HAMA responses to tositumomab.
- Alexandra M. Levine, MD Robert S.
Mocharnuk, MD
Rituximab, Tositumomab (Bexxar), Ibritumomab (Zevalin): And the
Winner Is...
M
(free login req.)
|
Resources:
|
Resources
& Research News:
|
|
Survival benefit associated
with human anti-mouse antibody (HAMA) in patients with
B-cell malignancies. Cancer Immunol Immunother. 2006
Dec;55(12):1451-8.
Epub 2006 Feb 22. PMID:
16496145
Patients with B-cell malignancies that developed high HAMA
titers had longer survival
that was not explained by risk factors or histologic grade,
suggesting the importance of the
immune system.
|
|
|
-
|
